AstraZeneca's Baxfendy Approval: Strategic Implications for Hypertension Market

AstraZeneca's Baxfendy Approval: Strategic Implications for Hypertension Market | AstraZeneca Intelligence | Humanexa

Evidence Sources

Source-backed references used to construct this page.

[SHINSA]English Translation of Review Report: Blenrep, Neffy, and Tecentriq (Partial Change Approval)
PMDA
FDA document
View source
FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order
FDA
FDA document
View source
Rilzabrutinib authorised to treat adults with immune thrombocytopenia when prior treatments have been insufficient
MHRA
FDA document
View source
[KOKUSAI]Registration for the ASEAN-Japan Medical Devices Regulatory Symposium is now open.
PMDA
FDA document
View source
Draft rare disease therapies regulatory framework
MHRA
FDA document
View source
Landmark new plans bring treatments for rare diseases a step closer
MHRA
FDA document
View source
Remote Hypertension Management for Black Patients
ClinicalTrials.gov
FDA document
View source
Randomized Controlled Study on the Safety and Efficacy of Phage Cocktail in the Treatment of Multidrug-Resistant Bacterial Skin Infections
ClinicalTrials.gov
FDA document
View source
Exploring the Feasibility of Transcranial Ultrasound Stimulation in the Treatment of Schizophrenia
ClinicalTrials.gov
FDA document
View source
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
Bristol Myers Squibb
FDA document
View source
Safety and efficacy of ashwagen (a standardized withania somnifera extract) in stress and anxiety with hypertension and associated cardiometabolic risk factors: a randomized, placebo-controlled trial.
PubMed
FDA document
View source
Observation of the therapeutic effect of flunarizine capsules combined with the Epley manoeuvre in the treatment of benign paroxysmal positional vertigo.
PubMed
FDA document
View source
Oral propranolol treatment safety in infantile hemangiomas.
PubMed
FDA document
View source
Sirolimus-based treatment regimens for antinuclear antibody (ANA)-positive immune thrombocytopenia: a retrospective single-center cohort study.
PubMed
FDA document
View source
Efficacy and tolerability of linezolid as an adjunctive treatment for nontuberculous mycobacterial infections in patients with adult-onset immunodeficiency syndrome: a prospective cohort study.
PubMed
FDA document
View source
Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMed
FDA document
View source
AstraZeneca's Baxfendy Receives US Approval for Hypertension as First-in-Class Treatment
AstraZeneca
FDA document
View source
FDA Drug Competition Action Plan | Improving the efficiency of the generic drug development, review, and approval process
FDA
FDA document
View source
Competitive Generic Therapy Approvals
FDA
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDA
FDA document
View source

AstraZeneca's Baxfendy Approval: Strategic Implications for Hypertension Market

Asset Overview

Company Context

Regulatory Timeline

FDA Drug Competition Action Plan | Improving the efficiency of the generic drug development, review, and approval process

Competitive Generic Therapy Approvals

[SHINSA]English Translation of Review Report: Blenrep, Neffy, and Tecentriq (Partial Change Approval)

FDA AP — BAXFENDY (ORIG)

Novel Drug Approvals for 2026

Related Signals

Evidence Sources